Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Department of Psychiatry, University of Campania “L. Vanvitelli”, Naples, Italy; 2 Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, The Netherlands; 3 Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maas- tricht University Medical Center, Maastricht, The Netherlands; 4 Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 5 University Psychiatric Centre KU Leuven, Kortenberg, Belgium; 6 Antwerp Health Law and Ethics Chair, University of Antwerp, Antwerp, Belgium; 7 De- partment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University Düsseldorf, LVR-Klinikum Düsseldorf, and WHO Collaborating Center on Quality Assurance and Empowerment in Mental Health, Düsseldorf, Germany; 8 Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA; 9 Department of Veterans Affairs, Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA; 10Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 11Di- vision of Psychology, Department of Psychiatry, University of Miami Miller School of Medicine, Miami, FL, USA; 12Department of Psychiatry, University of Cambridge and Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK; 13Department of Psychiatry and Neuroscience, Ichan Med- ical School at Mount Sinai, New York, NY, USA; 14Orygen, Parkville, VIC, Australia; 15Centre for Youth Mental Health, University of Melbourne, Parkville, VIC, Australia; 16Centre for Life Course Health Research, University of Oulu, Oulu, Finland; 17Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; 18Semel Institute for Neuroscience and Human Behavior, Geffen School of Medicine, and Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA; 19Mental Health Department, Servicio Navarro de Salud, Instituto de Investi- gación Sanitaria de Navarra, Pamplona, Spain; 20Centre for Global Mental Health and Centre for Implementation Science, Institute of Psychiatry, Psy- chology & Neuroscience, King’s College London, London, UK; 21University Psychiatric Center KU Leuven, Leuven, Belgium
Список исп. литературыСкрыть список 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013. 2. World Health Organization. ICD-11 guidelines. https://gcp.network/en/. 3. Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry 2019;18:146-61. 4. Sartorius N, Chiu H, Heok KE et al. Name change for schizophrenia. Schizophr Bull 2014;40:255-8. 5. Perälä J, Suvisaari J, Saarni SI et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007;64:19-28. 6. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4-10. 7. Bighelli I, Salanti G, Huhn M et al. Psychological interventions to reduce positive symptoms in schizophrenia: a systematic review and network meta-analysis. World Psychiatry 2018;17:316-29. 8. Drake RE, Essock SM. The science-to-service gap in real-world schizophrenia treatment: the 95% problem. Schizophr Bull 2009;35:677-8. 9. McFarlane WR. Family interventions for schizophrenia and the psychoses: a review. Family Process 2016;55:460-82. 10. Bond GR, Becker DR, Drake RE et al. Implementing supported employment as an evidence-based practice. Psychiatr Serv 2001; 52:313-22. 11. De Hert M, Detraux J. Reversing the downward spiral for people with severe mental illness through educational innovations. World Psychiatry 2017;16:41-2. 12. Fleischhacker WW, Arango C, Arteel P et al. Schizophrenia – time to commit to policy change. Schizophr Bull 2014;40(Suppl. 3):S165-94. 13. Pincus HA, Spaeth-Rublee B, Grant S et al. A review of mental health recovery programs in selected industrialized countries. Int J Ment Health Syst 2016;10:73. 14. Maj M, Stein DJ, Parker G et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry 2020;19:269-93. 15. Kessler RC. The potential of predictive analytics to provide clinical decision support in depression treatment planning. Curr Opin Psychiatry 2018;31:32-9. 16. Sass LA. Self-disturbance and schizophrenia: structure, specificity, pathogenesis (current issues, new directions). Schizophr Res 2014;152:5-11. 17. Parnas J. The core Gestalt of schizophrenia. World Psychiatry 2012;11:67-9. 18. Parnas J, Møller P, Kircher T et al. EASE: Examination of Anomalous Self-Experience. Psychopathology 2005;38:236-58. 19. Nordgaard J, Parnas J. Self-disorders and the schizophrenia spectrum: a study of 100 first hospital admissions. Schizophr Bull 2014;40:1300-7. 20. Cicero DC, Neis AM, Klaunig MJ et al. The Inventory of Psychotic-Like Anomalous Self-Experiences (IPASE): development and validation. Psychol Assess 2017;29:13-25. 21. Nelson B, Li E, Cicero DC et al. The construct validity of the Inventory of Psychotic-Like Anomalous Self-Experiences (IPASE) as a measure of minimal self-disturbance: preliminary data. Early Interv Psychiatry 2019;13:686-91. 22. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005;39:964-71. 23. Konings M, Bak M, Hanssen M et al. Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr Scand 2006;114:55-61. 24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. 25. Kay SR, Opler RA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) manual. Toronto: Multi-Health Systems Inc., 2000. 26. Ostergaard SD, Lemming OM, Mors O et al. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand 2016;133:436-44. 27. Lincoln TM, Ziegler M, Lüllmann E et al. Can delusions be self-assessed? Concordance between self- and observer-rated delusions in schizophrenia. Psychiatry Res 2010;178:249-54. 28. Carey TA, Mullan RJ. What is Socratic questioning? Psychother Theor Res Pract Train 2004;41:217-26. 29. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394:939-51. 30. Howes OD, McCutcheon R, Agid O et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017;174:216-29. 31. Gaebel W, Stricker J, Riesbeck M. The long-term antipsychotic treatment of schizophrenia: a selective review of clinical guidelines and clinical case examples. Schizophr Res (in press). 32. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 2018;17:149-60. 33. Murray RM, Quattrone D, Natesan S et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 2016;209:361-5. 34. Palmier-Claus J, Griffiths R, Murphy E et al. Cognitive behavioural therapy for thought disorder in psychosis. Psychosis 2017;9:347-57. 35. Trower P, Birchwood M, Meaden A et al. Cognitive therapy for command hallucinations: randomised controlled trial. Br J Psychiatry 2004;184:312-20. 36. Peters ER, Moritz S, Schwannauer M et al. Cognitive Biases Questionnaire for psychosis. Schizophr Bull 2014;40:300-13. 37. Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Leipzig: Deuticke, 1911. 38. Jackson JH. Selected writings. London: Hodder and Stoughton, 1931. 39. Harvey PD, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry 2012;11:73-9. 40. Galderisi S, Rossi A, Rocca P et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 2014;13:275-87. 41. Galderisi S, Mucci A, Buchanan RW et al. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry 2018;5:664-77. 42. Kirkpatrick B, Fenton WS, Carpenter WT Jr et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214-19. 43. Strauss GP, Esfahlani FZ, Galderisi S et al. Network analysis reveals the latent structure of negative symptoms in schizophrenia. Schizophr Bull 2019;45:1033-41. 44. Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017;16:14-24. 45. Mucci A, Merlotti E, Üçok A et al. Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr Res 2017;186:19-28. 46. Krause M, Zhu Y, Huhn M et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018;268:625-39. 47. Lutgens D, Gariepy G, Malla A. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. Br J Psychiatry 2017;210:324-32. 48. Turner DT, McGlanaghy E, Cuijpers P et al. A meta-analysis of social skills training and related interventions for psychosis. Schizophr Bull 2018;44:475-91. 49. Velthorst E, Koeter M, van der Gaag M et al. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol Med 2015;45:453-65. 50. Cella M, Preti A, Edwards C et al. Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. Clin Psychol Rev 2017;52:43-51. 51. Kennedy NI, Lee WH, Frangou S. Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: a meta-analysis of randomized controlled trials. Eur Psychiatry 2018;49:69-77. 52. Andreasen NC, Olsen S. Negative vs positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982;39:789-94. 53. Kirkpatrick B, Strauss GP, Nguyen L et al. The brief negative symptom scale: psychometric properties. Schizophr Bull 2011;37:300-5. 54. Kring AM, Gur RE, Blanchard JJ et al. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry 2013;170:165-72. 55. Peralta V, Gil-Berrozpe G, Librero J et al. The symptom and domain structure of psychotic disorders: a network analysis approach. Schizophr Bull Open (in press). 56. Minor KS, Lysaker PH. Necessary, but not sufficient: links between neurocognition, social cognition, and metacognition in schizophrenia are moderated by disorganized symptoms. Schizophr Res 2014;159:198-204. 57. Rocca P, Galderisi S, Rossi A et al. Disorganization and real-world functioning in schizophrenia: results from the multicenter study of the Italian Network for Research on Psychoses. Schizophr Res 2018;201:105-12. 58. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992;49:615-23. 59. Broome MR, Bottlender R, Rossler M. et al (eds). The AMDP System. Manual for assessment and documentation of psychopathology in psychiatry, 9th ed Boston: Hogrefe, 2018. 60. Andreasen NC. Scale for the assessment of thought, language, and communication (TLC). Schizophr Bull 1986;12:473-82. 61. Peralta V, Cuesta MJ. Motor abnormalities: from neurodevelopmental to neurodegenerative through «functional» (neuro)psychiatric disorders. Schizophr Bull 2017;43:956-71. 62. Bush G, Fink M, Petrides G et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996;93:129-36. 63. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville: US Department of Health, Education and Welfare, 1976. 64. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(Suppl. 212):11-9. 65. Gerlach J, Korsgaard S, Clemmesen P et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993;87:244-52. 66. Martino D, Karnik V, Osland S et al. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry 2018;63:730-9. 67. Peralta V, Cuesta MJ. Characterization of affective domains within the nonaffective psychotic disorders. Schizophr Res 2009;111:61-9. 68. Gonzalez-Pinto A, Gutierrez M, Mosquera F et al. First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord 1998;50:41-4. 69. Addington D, Addington J, Maticka-Tyndale E et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201-8. 70. Lysaker PH, Pattison ML, Leonhardt BL et al. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry 2018;17:12-23. 71. Amador XF, Strauss DH, Yale SA et al. Assessment of insight in psychosis. Am J Psychiatry 1993;150:873-9. 72. Beck AT, Baruch E, Balter JM et al. A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res 2004;68:319-29. 73. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24(Suppl. 4):81-90. 74. Posner K, Brown GK, Stanley B et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77. 75. Breslau N, Roth T, Rosenthal L et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-8. 76. Xiang YT, Weng YZ, Leung CM et al. Prevalence and correlates of insomnia and its impact on quality of life in Chinese schizophrenia patients. Sleep 2009;32:1059. 77. Alam A, Chengappa KR, Ghinassi F. Screening for obstructive sleep apnea among individuals with severe mental illness at a primary care clinic. Gen Hosp Psychiatry 2012;34:660-4. 78. van Os J, Reininghaus U. The clinical epidemiology of schizophrenia In: Kaplan B, Sadock J, Sadock V. et al (eds). Kaplan & Sadock’s comprehensive textbook of psychiatry, 10th ed London: Lippincott Williams & Wilkins, 2017. 79. Singh SP, Cooper JE, Fisher HL et al. Determining the chronology and components of psychosis onset: the Nottingham Onset Schedule (NOS). Schizophr Res 2005;80:117-30. 80. Perkins DO, Leserman J, Jarskog LF et al. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res 2000;44:1-10. 81. Sartorius N, Shapiro R, Kimura M et al. WHO International Pilot Study of Schizophrenia. Psychol Med 1972;2:422-5. 82. Johnstone EC, Frith CD, Crow TJ et al. The Northwick Park ’Functional' Psychosis Study: diagnosis and outcome. Psychol Med 1992;22:331-46. 83. Tsuang MT, Dempsey GM. Long-term outcome of major psychoses. II. Schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group. Arch Gen Psychiatry 1979;36:1302-4. 84. Susser E, Finnerty M, Mojtabai R et al. Reliability of the Life Chart Schedule for assessment of the long-term course of schizophrenia. Schizophr Res 2000;42:67-77. 85. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006;36:1349-62. 86. Llewellyn-Beardsley J, Rennick-Egglestone S, Callard F et al. Characteristics of mental health recovery narratives: systematic review and narrative synthesis. PLoS One 2019;14:e0214678. 87. Corrigan PW, Salzer M, Ralph RO et al. Examining the factor structure of the Recovery Assessment Scale. Schizophr Bull 2004;30:1035-41. 88. Carter L, Read J, Pyle M et al. The impact of causal explanations on outcome in people experiencing psychosis: a systematic review. Clin Psychol Psychother 2017;24:332-47. 89. Nuechterlein KH, Green MF, Kern R. Schizophrenia as a cognitive disorder: recent approaches to identifying its core cognitive components to aid treatment development In: Gattaz WF, Busatto G. (eds). Advances in schizophrenia research 2009. New York: Springer, 2009:267-82. 90. Cornblatt B, Obuchowski M, Roberts S et al. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999;11:487-508. 91. Nuechterlein KH, Dawson ME, Gitlin M et al. Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr Bull 1992;18:387-425. 92. Snitz BE, MacDonald AW 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006;32:179-94. 93. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30. 94. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004;72:5-9. 95. Nuechterlein KH, Barch DM, Gold JM et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39. 96. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45. 97. Kern RS, Gold JM, Dickinson D et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res 2011;126:124-31. 98. Grant PM, Best MW, Beck AT. The meaning of group differences in cognitive test performance. World Psychiatry 2019;18:163-4. 99. Green MF, Kern RS, Braff DL et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 2000;26:119-36. 100. Fett AKJ, Viechtbauer W, Dominguez MG et al. The relationship between neurocognition and social cognition and functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 2011;35:573-88. 101. Nuechterlein KH, Green MF, Kern RS et al. The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. Am J Psychiatry 2008;165:203-13. 102. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery Manual, 3rd ed. Los Angeles: MATRICS Assessment, Inc., 2016. 103. Robbins TW, James M, Owen AM et al. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994;5:266-81. 104. Pietrzak RH, Olver J, Norman T et al. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 2009;31:848-59. 105. Keefe RSE, Goldberg TE, Harvey PD et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68:283-97. 106. Randolph C, Tierney MC, Mohr E et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-9. 107. Velligan DI, DiCocco M, Bow-Thomas CC et al. A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr Res 2004;71:273-83. 108. Hurford IM, Marder SR, Keefe RS et al. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull 2011;37:538-45. 109. Ventura J, Reise SP, Keefe RS et al. The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition. Schizophr Bull 2013;39:583-91. 110. Keefe RS, Poe M, Walker TM et al. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry 2006;163:426-32. 111. Wykes T, Huddy V, Cellard C et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011;168:472-85. 112. Firth J, Stubbs B, Rosenbaum S et al. Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2017;43:546-56. 113. Nuechterlein KH, Ventura J, McEwen SC et al. Enhancing cognitive training through aerobic exercise after a first schizophrenia episode: theoretical conception and pilot study. Schizophr Bull 2016;42(Suppl. 1):S44-52. 114. Best MW, Milanovic M, Iftene F et al. A randomized controlled trial of executive functioning training compared with perceptual training for schizophrenia spectrum disorders: effects on neurophysiology, neurocognition, and functioning. Am J Psychiatry 2019;176:297-306. 115. Medalia A, Saperstein AM, Qian M et al. Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia. Schizophr Res 2019;208:397-405. 116. Green MF, Penn DL, Bentall R et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull 2008;34:1211-20. 117. Savla GN, Vella L, Armstrong CC et al. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr Bull 2013;39:979-92. 118. Healey KM, Bartholomeusz CF, Penn DL. Deficits in social cognition in first episode psychosis: a review of the literature. Clin Psychol Rev 2016;50:108-37. 119. Nahum M, Fisher M, Loewy R et al. A novel, online social cognitive training program for young adults with schizophrenia: a pilot study. Schizophr Res Cogn 2014;1:e11-9. 120. Kurtz MM, Gagen E, Rocha NBF et al. Comprehensive treatments for social cognitive deficits in schizophrenia: a critical review and effect-size analysis of controlled studies. Clin Psychol Rev 2016;43:80-9. 121. Horan WP, Dolinsky M, Lee J et al. Social cognitive skills training for psychosis with community-based training exercises: a randomized controlled trial. Schizophr Bull 2018;44:1254-66. 122. Burkner PC, Williams DR, Simmons TC et al. Intranasal oxytocin may improve high-level social cognition in schizophrenia, but not social cognition or neurocognition in general: a multilevel Bayesian meta-analysis. Schizophr Bull 2017;43:1291-303. 123. Davis MC, Green MF, Lee J et al. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 2014;39:2070-7. 124. Pinkham AE, Penn DL, Green MF et al. Social cognition psychometric evaluation: results of the Initial Psychometric Study. Schizophr Bull 2016;42:494-504. 125. Kern RS, Penn DL, Lee J et al. Adapting social neuroscience measures for schizophrenia clinical trials, part 2: Trolling the depths of psychometric properties. Schizophr Bull 2013;39:1201-10. 126. Horan WP, Green MF. Treatment of social cognition in schizophrenia: current status and future directions. Schizophr Res 2019;203:3-11. 127. McDonald S, Flanagan S, Rollins J. The Awareness of Social Inference Test. Suffolk: Thames Valley Test Company, 2002. 128. Mayer JD, Salovey P, Caruso DR. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) user’s manual. Toronto: MHS Publishers, 2002. 129. Bryson G, Bell M, Lysaker P. Affect recognition in schizophrenia: a function of global impairment or a specific cognitive deficit. Psychiatry Res 1997;71:105-13. 130. Kraepelin E. Psychiatrie. Ein Lehrbuch für Studirende und Aerzte. Fünfte, vollständig umgearbeitete Auflage. Leipzig: Barth, 1896. 131. Fish B. The detection of schizophrenia in infancy: a preliminary report. J Nerv Ment Dis 1957;125:1-24. 132. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9. 133. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? BMJ 1987;295:681-2. 134. Jones P, Rodgers B, Murray R et al. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994;344:1398-402. 135. Isohanni M, Jones PB, Moilanen K et al. Early developmental milestones in adult schizophrenia and other psychoses. A 31-year follow-up of the Northern Finland 1966 Birth Cohort. Schizophr Res 2001;52:1-19. 136. Cannon M, Caspi A, Moffitt TE et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 2002;59:449-56. 137. Khandaker GM, Barnett JH, White IR et al. A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophr Res 2011;132:220-7. 138. Heinrichs DW, Buchanan RW. Significance and meaning of neurological signs in schizophrenia. Am J Psychiatry 1988;145:11-8. 139. Fish B, Marcus J, Hans SL et al. Infants at risk for schizophrenia: sequelae of a genetic neurointegrative defect. Arch Gen Psychiatry 1992;49:221-35. 140. Green MF, Satz P, Christenson C. Minor physical anomalies in schizophrenia patients, bipolar patients, and their siblings. Schizophr Bull 1994;20:433-40. 141. Larson FV, Wagner AP, Jones PB et al. Psychosis in autism: comparison of the features of both conditions in a dually affected cohort. Br J Psychiatry 2017;210:269-75. 142. Downs JM, Lechler S, Dean H et al. The association between comorbid autism spectrum disorders and antipsychotic treatment failure in early-onset psychosis: a historical cohort study using electronic health records. J Clin Psychiatry 2017;78:e1233-41. 143. Khandaker GM, Stochl J, Zammit S et al. A population-based longitudinal study of childhood neurodevelopmental disorders, IQ and subsequent risk of psychotic experiences in adolescence. Psychol Med 2014;44:3229-38. 144. Sanders RD, Keshavan MS. The neurologic examination in adult psychiatry: from soft signs to hard science. J Neuropsychiatry Clin Neurosci 1998;10:395-404. 145. Chen EY, Shapleske J, Luque R et al. The Cambridge Neurological Inventory: a clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res 1995;56:183-204. 146. Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res 1989;27:335-50. 147. Cannon-Spoor H, Potkin S, Wyatt R. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982;8:470-84. 148. Van Mastrigt S, Addington J. Assessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale. J Psychiatry Neurosci 2002;27:92-101. 149. Leung WW, Bowie CR, Harvey PD. Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study. J Int Neuropsychol Soc 2008;14:479-88. 150. Granholm E, Holden JL, Mikhael T et al. What do people with schizophrenia do all day? Ecological momentary assessment of real-world functioning in schizophrenia. Schizophr Bull 2020;46:242-51. 151. Gard DE, Kring AM, Gard MG et al. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 2007;93:253-60. 152. Sitzer DI, Twamley EW, Patterson TL et al. Multivariate predictors of social skills performance in middle-aged and older out-patients with schizophrenia spectrum disorders. Psychol Med 2008;38: 755-63. 153. Robertson BR, Prestia D, Twamley EW et al. Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia. Schizophr Res 2014;160:136-41. 154. Granholm E, Holden J, Link PC et al. Randomized clinical trial of cognitive behavioral social skills training for schizophrenia: improvement in functioning and experiential negative symptoms. J Consult Clin Psychol 2014;82:1173-85. 155. Harvey PD, Raykov T, Twamley EW et al. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am J Psychiatry 2011;168:1195-201. 156. Morosini PL, Magliano L, Brambilla L et al. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-9. 157. Gard DE, Gard MG, Kring AM et al. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J Res Pers 2006;40:1086-102. 158. Llerena K, Park SG, McCarthy JM et al. The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry 2013;54:568-74. 159. Schlosser DA, Campellone TR, Truong B et al. Efficacy of PRIME, a mobile app intervention designed to improve motivation in young people with schizophrenia. Schizophr Bull 2018;44:1010-20. 160. Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull 2012;38:304-15. 161. Durand D, Strassnig M, Sabbag S et al. Factors influencing self-assessment of cognition and functioning in schizophrenia: implications for treatment studies. Eur Neuropsychopharmacol 2015;25:185-91. 162. World Health Organization. The World Health Organization Quality of Life (WHOQOL). www.who.int. 163. Button B. Quality of Well-Being (QWB) Scale In: Michalos AC. (eds). Encyclopedia of quality of life and well-being research. Dordrecht: Springer, 2016. 164. Slade M, Leese M, Ruggeri M et al. Does meeting needs improve quality of life? Psychother Psychosom 2004;73:183-9. 165. Drukker M, van Dillen K, Bak M et al. The use of the Camberwell Assessment of Need in treatment: what unmet needs can be met? Soc Psychiatry Psychiatr Epidemiol 2008;43:410-7. 166. Maslow AH. Toward a psychology of being. Princeton: Van Nostrand, 1962. 167. Lasalvia A, Bonetto C, Tansella M et al. Does staff-patient agreement on needs for care predict a better mental health outcome? A 4-year follow-up in a community service. Psychol Med 2008;38:123-33. 168. Puschner B, Becker T, Mayer B et al. Clinical decision making and outcome in the routine care of people with severe mental illness across Europe (CEDAR). Epidemiol Psychiatr Sci 2016;25:69-79. 169. Drukker M, Joore M, van Os J et al. The use of a cumulative needs for care monitor for individual treatment v. care as usual for patients diagnosed with severe mental illness, a cost-effectiveness analysis from the health care perspective. Epidemiol Psychiatr Sci 2012;21:381-92. 170. Drukker M, van Os J, Dietvorst M et al. Does monitoring need for care in patients diagnosed with severe mental illness impact on psychiatric service use? Comparison of monitored patients with matched controls. BMC Psychiatry 2011;11:45. 171. Drukker M, van Os J, Bak M et al. Systematic monitoring of needs for care and global outcomes in patients with severe mental illness. BMC Psychiatry 2010;10:36. 172. Slade M, Phelan M, Thornicroft G et al. The Camberwell Assessment of Need (CAN): comparison of assessments by staff and patients of the needs of the severely mentally ill. Soc Psychiatry Psychiatr Epidemiol 1996;31:109-13. 173. Phelan M, Slade M, Thornicroft G et al. The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br J Psychiatry 1995;167:589-95. 174. Bond GR, Drake RE, Becker DR. An update on Individual Placement and Support. World Psychiatry 2020;19:390-1. 175. McGorry PD, Hickie IB. (eds). Clinical staging in psychiatry: making diagnosis work for research and treatment. Cambridge: Cambridge University Press, 2019. 176. McGorry PD, Hickie IB, Yung AR et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006;40:616-22. 177. Shah JL, Scott J, McGorry PD et al. Transdiagnostic clinical staging in youth mental health: a first international consensus statement. World Psychiatry 2020;19:233-42. 178. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993;87:225-30. 179. McGorry PD, Hartmann JA, Spooner R et al. Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry. World Psychiatry 2018;17:133-42. 180. McGorry PD, Ratheesh A, O’Donoghue B. Early intervention – an implementation challenge for 21st century mental health care. JAMA Psychiatry 2018;75:545-6. 181. Correll CU, Galling B, Pawar A et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry 2018;75:555-65. 182. Frances A. Saving normal: an insider’s revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life. New York: Morrow, 2013. 183. Insel TR. The arrival of preemptive psychiatry. Early Interv Psychiatry 2007;1:5-6. 184. Hegelstad WT, Larsen TK, Auestad B et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry 2012;169:374-80. 185. Kane JM, Robinson DG, Schooler NR et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. Am J Psychiatry 2016;173:362-72. 186. Francey S, O’Donoghue B, Nelson B et al. Psychosocial intervention with or without antipsychotic medication for first episode psychosis: a randomized noninferiority clinical trial. Schizophr Bull Open (in press). 187. Orygen . Australian clinical guidelines for early psychosis, 2nd ed Melbourne: Orygen, The National Centre of Excellence in Youth Mental Health, 2016. 188. Thien K, Bowtell M, Eaton S et al. Clozapine use in early psychosis. Schizophr Res 2018;199:374-9. 189. Killackey E, Allott K, Jackson HJ et al. Individual placement and support for vocational recovery in first-episode psychosis: randomised controlled trial. Br J Psychiatry 2019;214:76-82. 190. Wunderink L, Nieboer RM, Wiersma D et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013;70:913-20. 191. First MB, Williams JBW, Karg RS et al. Structured Clinical Interview for DSM-5 – Research Version. Arlington: American Psychiatric Association, 2015. 192. Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull 2017;43:240-4. 193. Heimberg RG, Horner KJ, Juster HR et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999;29:199-212. 194. Sharma LP, Reddy YCJ. Obsessive-compulsive disorder comorbid with schizophrenia and bipolar disorder. Indian J Psychiatry 2019;61(Suppl. 1):S140-8. 195. Goodman WK, Price LH, Rasmussen SA et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11. 196. Malaspina D, Walsh-Messinger J, Brunner A et al. Features of schizophrenia following premorbid eating disorders. Psychiatry Res 2019;278:275-80. 197. Peralta V, de Jalón EG, Campos MS et al. The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis. Schizophr Res 2011;126:28-35. 198. Hartz SM, Pato CN, Medeiros H et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71:248-54. 199. Hare RD. The Hare Psychopathy Checklist-Revised. North Tonawanda: Multi-Health Systems, 1991. 200. Oakley P, Kisely S, Baxter A, et al. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis. J Psychiatr Res 2018;102:245-53. 201. De Hert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77. 202. Correll CU, Detraux J, De Lepeleire J et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119-36. 203. Firth J, Siddiqi N, Koyanagi A et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019;6:675-712. 204. Vancampfort D, Stubbs B, Mitchell AJ et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14:339-47. 205. De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci 2018;20:31-40. 206. Vancampfort D, Correll CU, Galling B et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166-74. 207. Correll CU, Solmi M, Veronese N et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16:163-80. 208. De Hert M, Cohen D, Bobes J et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10:138-51. 209. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;138:e426-83. 210. Garg N, Muduli SK, Kapoor A et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J 2017;69:458-63. 211. WHO CVD Risk Chart Working Group . World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019;7:e1332-45. 212. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099. 213. Yusuf S, Joseph P, Rangarajan S et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 2020;395:795-808. 214. Rosengren A, Hawken S, Ounpuu S et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:953-62. 215. Vancampfort D, Firth J, Schuch FB et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 2017;16:308-15. 216. Annamalai A, Tek C. An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. Int J Endocrinol 2015;2015:969182. 217. Vancampfort D, Firth J, Correll CU et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 2019;18:53-66. 218. Tumiel E, Wichniak A, Jarema M et al. Nonpharmacological interventions for the treatment of cardiometabolic risk factors in people with schizophrenia – a systematic review. Front Psychiatry 2019;10:566. 219. Luo F, Das A, Chen J et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol 2019;18:54. 220. McGinty EE, Baller J, Azrin ST et al. Interventions to address medical conditions and health risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull 2016;42:96-124. 221. Shawen AE, Drayton SJ. Review of pharmacotherapy for smoking cessation in patients with schizophrenia. Ment Health Clin 2018;8:78-85. 222. Gates J, Killackey E, Phillips L et al. Mental health starts with physical health: current status and future directions of non-pharmacological interventions to improve physical health in first-episode psychosis. Lancet Psychiatry 2015;2:726-42. 223. Torous J, Andersson G, Bertagnoli A et al. Towards a consensus around standards for smartphone apps and digital mental health. World Psychiatry 2019;18:97-8. 224. Rasic D, Hajek T, Alda M et al. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. Schizophr Bull 2014;40:28-38. 225. Yang J, Visscher PM, Wray NR. Sporadic cases are the norm for complex disease. Eur J Hum Genet 2010;18:1039-43. 226. Mortensen PB, Pedersen MG, Pedersen CB. Psychiatric family history and schizophrenia risk in Denmark: which mental disorders are relevant? Psychol Med 2010;40:201-10. 227. Cross-Disorder Group of the Psychiatric Genomics Consortium , Lee SH, Ripke S et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013;45:984-94. 228. Cross-Disorder Group of the Psychiatric Genomics Consortium, Genetic Risk Outcome of Psychosis Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013;381:1371-9. 229. Agerbo E, Sullivan PF, Vilhjalmsson BJ et al. Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: a Danish population-based study and meta-analysis. JAMA Psychiatry 2015;72:635-41. 230. Vigod SN, Kurdyak PA, Dennis CL et al. Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study. BJOG 2014;121:566-74. 231. Zhong QY, Gelaye B, Fricchione GL et al. Adverse obstetric and neonatal outcomes complicated by psychosis among pregnant women in the United States. BMC Pregnancy Childbirth 2018;18:120. 232. Gantriis DL, Thorup AAE, Harder S et al. Home visits in the Danish High Risk and Resilience Study – VIA 7: assessment of the home environment of 508 7-year-old children born to parents diagnosed with schizophrenia or bipolar disorder. Acta Psychiatr Scand 2019;140:126-34. 233. Simoila L, Isometsa E, Gissler M et al. Maternal schizophrenia and out-of-home placements of offspring: a national follow-up study among Finnish women born 1965-1980 and their children. Psychiatry Res 2019;273:9-14. 234. de Sousa P, Varese F, Sellwood W et al. Parental communication and psychosis: a meta-analysis. Schizophr Bull 2014;40:756-68. 235. Ranning A, Laursen T, Agerbo E et al. School performance from primary education in the adolescent offspring of parents with schizophrenia and bipolar disorder – a national, register-based study. Psychol Med 2018;48:1993-2000. 236. Kallquist A, Salzmann-Erikson M. Experiences of having a parent with serious mental illness: an interpretive meta-synthesis of qualitative literature. J Child Fam Stud 2019;28:2056-68. 237. NIMH Genetics Initiative. Family Interview for Genetic Studies (FIGS). Rockville: National Institute of Mental Health, 1992. 238. Nurnberger JI Jr, Blehar MC, Kaufmann CA et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849-59. 239. Weissman MM, Wickramaratne P, Adams P et al. Brief screening for family psychiatric history: the Family History Screen. Arch Gen Psychiatry 2000;57:675-82. 240. Esterberg ML, Trotman HD, Holtzman C et al. The impact of a family history of psychosis on age-at-onset and positive and negative symptoms of schizophrenia: a meta-analysis. Schizophr Res 2010;120:121-30. 241. Kakela J, Panula J, Oinas E et al. Family history of psychosis and social, occupational and global outcome in schizophrenia: a meta-analysis. Acta Psychiatr Scand 2014;130:269-78. 242. Immonen J, Jaaskelainen E, Korpela H et al. Age at onset and the outcomes of schizophrenia: a systematic review and meta-analysis. Early Interv Psychiatry 2017;11:453-60. 243. Kowalec K, Lu Y, Sariaslan A et al. Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study. Mol Psychiatry (in press). 244. Mirdal GKM, Mednick SA, Schulsinger F et al. Perinatal complications in children of schizophrenic mothers. Acta Psychiatr Scand 1974;50:553-6. 245. McNeil TF, Kaij L. Obstetric factors in the development of schizophrenia: complications in the birth of preschizophrenics and in reproduction by schizophrenic parents In: Wynne LC, Cromwell RL, Matthysse S. (eds). The nature of schizophrenia. New York: Wiley, 1978:401-29. 246. Lewis SW, Murray RM. Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. J Psychiatr Res 1987;21:413-21. 247. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytical review. Am J Psychiatry 2002;159:1080-92. 248. Davies C, Segre G, Estradé A et al. Prenatal and perinatal risk factors for psychosis: a meta-analysis. Lancet Psychiatry 2020;7:399-41. 249. Walshe M, McDonald C, Boydell J et al. Long-term maternal recall of obstetric complications in schizophrenia research. Psychiatry Res 2011;187:335-40. 250. Lewis SW, Murray RM, Owen MJ. Obstetric complications in schizophrenia: methodology and mechanisms In: Schulz SC, Tamminga CA. (eds). Schizophrenia: scientific progress. New York: Oxford University Press, 1989:56-68. 251. McNeil TF, Sjöström K. A comprehensive scale for assessing obstetric complications. Malmo: Lund University, 1994. 252. Breeman LD, Jaekel J, Baumann N et al. Preterm cognitive function into adulthood. Pediatrics 2015;136:415-23. 253. Karolis VR, Froudist-Walsh S, Kroll J et al. Volumetric grey matter alterations in adolescents and adults born very preterm suggest accelerated brain maturation. Neuroimage 2017;163:379-89. 254. Froudist-Walsh S, Bloomfield MA, Veronese M et al. The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life. eLife 2017;6:e29088. 255. Radua J, Ramella-Cravaro V, Ioannidis JP et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018;17:49-66. 256. Belbasis L, Köhler C, Stefanis N et al. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. Acta Psychiatr Scand 2018;137:88-97. 257. Morgan C, Knowles G, Hutchinson G. Migration, ethnicity and psychoses: evidence, models and future directions. World Psychiatry 2019;18:247-58. 258. Guloksuz S, Rutten BP, Pries L-K et al. The complexities of evaluating the exposome in psychiatry: a data-driven illustration of challenges and some propositions for amendments. Schizophr Bull 2018;44:1175-9. 259. Hailes HP, Yu R, Danese A et al. Long-term outcomes of childhood sexual abuse: an umbrella review. Lancet Psychiatry 2019;6:830-9. 260. Pries L-K, Guloksuz S, Ten Have M et al. Evidence that environmental and familial risks for psychosis additively impact a multidimensional subthreshold psychosis syndrome. Schizophr Bull 2018;44:710-9. 261. Guloksuz S, Pries L-K, Delespaul P et al. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry 2019;18:173-82. 262. Thomas S, Höfler M, Schäfer I et al. Childhood maltreatment and treatment outcome in psychotic disorders: a systematic review and meta-analysis. Acta Psychiatr Scand 2019;140:295-312. 263. Bloomfield MA, Yusuf FN, Srinivasan R et al. Trauma-informed care for adult survivors of developmental trauma with psychotic and dissociative symptoms: a systematic review of intervention studies. Lancet Psychiatry 2020;7:449-62. 264. Bernstein DP, Fink L, Handelsman L et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 1994;151:1132-6. 265. Bifulco A, Brown GW, Harris TO . Childhood Experience of Care and Abuse (CECA): a retrospective interview measure. J Child Psychol Psychiatry 1994;35:1419-35. 266. Weissman MM, Pathak J, Talati A. Personal life events – a promising dimension for psychiatry in electronic health records. JAMA Psychiatry 2020;77:115-6. 267. Schäfer M, Korn S, Smith PK et al. Lonely in the crowd: recollections of bullying. Br J Dev Psychol 2004;22:379-94. 268. Thabrew H, de Sylva S, Romans S. Evaluating childhood adversity In: Fava GA, Sonino N, Wise TN. (eds). The psychosomatic assessment. Basel: Karger, 2012:35-57. 269. Brand RM, McEnery C, Rossell S et al. Do trauma-focussed psychological interventions have an effect on psychotic symptoms? A systematic review and meta-analysis. Schizophr Res 2018;195: 13-22. 270. Britto PR, Lye SJ, Proulx K et al. Nurturing care: promoting early childhood development. Lancet 2017;389:91-102. 271. Beards S, Gayer-Anderson C, Borges S et al. Life events and psychosis: a review and meta-analysis. Schizophr Bull 2013;39:740-7. 272. Shakoor S, Zavos HMS, Haworth CMA et al. Association between stressful life events and psychotic experiences in adolescence: evidence for gene-environment correlations. Br J Psychiatry 2018;208:532-8. 273. Bhavsar V, Boydell J, McGuire P et al. Childhood abuse and psychotic experiences – evidence for mediation by adulthood adverse life events. Epidemiol Psychiatr Sci 2017;28:300-9. 274. Lataster J, Myin-Germeys I, Lieb R et al. Adversity and psychosis: a 10-year prospective study investigating synergism between early and recent adversity in psychosis. Acta Psychiatr Scand 2012;125:388-99. 275. Brown G, Harris T. Life events and illness. New York: Guilford, 1989. 276. Holmes TH, Rahe RH. The Social Readjustment Rating Scale. J Psychosom Res 1967;11:213-8. 277. Dohrenwend BS, Askenasy AR, Krasnoff L et al. Exemplification of a method for scaling life events: the PERI Life Events Scale. J Health Soc Behav 1978;19:205-29. 278. Butjosa A, Gómez-Benito J, Myin-Germeys I et al. Development and validation of the Questionnaire of Stressful Life Events (QSLE). J Psychiatr Res 2017;95:213-23. 279. DeVylder JE, Koyanagi A, Unick J et al. Stress sensitivity and psychotic experiences in 39 low- and middle-income countries. Schizophr Bull 2016;42:1353-62. 280. Rauschenberg C, van Os J, Cremers D et al. Stress sensitivity as a putative mechanism linking childhood trauma and psychopathology in youth’s daily life. Acta Psychiatr Scand 2017;136:373-88. 281. DeVylder JE, Ben-David S, Schobel SA et al. Temporal association of stress sensitivity and symptoms in individuals at clinical high risk for psychosis. Psychol Med 2012;43:259-68. 282. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385-96. 283. Tso IF, Grove TB, Taylor SF. Self-assessment of psychological stress in schizophrenia: preliminary evidence of reliability and validity. Psychiatry Res 2012;195:39-44. 284. Myin-Germeys I, Kasanova Z, Vaessen T et al. Experience sampling methodology in mental health research: new insights and technical developments. World Psychiatry 2018;17:123-32. 285. Marconi A, Di Forti M, Lewis CM et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016;42:1262-9. 286. van Winkel R, Kuepper R. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annu Rev Clin Psychol 2014;10:767-91. 287. Large M, Mullin K, Gupta P et al. Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Aust N Z J Psychiatry 2014;48:418-32. 288. Schoeler T, Petros N, Di Forti M et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry 2017;4:627-33. 289. Di Forti M, Quattrone D, Freeman TP et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 2019;6:427-36. 290. Hjorthoj CR, Baker A, Fohlmann A et al. Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis systematic review and meta-analysis. Curr Pharm Des 2014;20:2205-11. 291. Rossi A, Galderisi S, Rocca P et al. Personal resources and depression in schizophrenia: the role of self-esteem, resilience and internalized stigma. Psychiatry Res 2017;256:359-64. 292. Rossi A, Galderisi S, Rocca P et al. The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. Eur Arch Psychiatry Clin Neurosci 2017;267:285-94. 293. Tian CH, Feng XJ, Yue M et al. Positive coping and resilience as mediators between negative symptoms and disability among patients with schizophrenia. Front Psychiatry 2019;10:641. 294. Meyer B. Coping with severe mental illness: relations of the Brief COPE with symptoms, functioning, and well-being. J Psychopathol Behav Assess 2001;23:265-77. 295. Ventura J, Subotnik KL, Ered A et al. The relationship of attitudinal beliefs to negative symptoms, neurocognition, and daily functioning in recent-onset schizophrenia. Schizophr Bull 2014;40:1308-18. 296. Mizuno Y, Wartelsteiner F, Frajo-Apor B. Resilience research in schizophrenia: a review of recent developments. Curr Opin Psychiatry 2016;29:218-23. 297. Hofer A, Mizuno Y, Frajo-Apor B et al. Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: cultural comparison in Austria and Japan. Schizophr Res 2016;171:86-91. 298. Ventura J, Nuechterlein KH, Subotnik KL et al. Self-efficacy and neurocognition may be related to coping responses in recent-onset schizophrenia. Schizophr Res 2004;69:343-52. 299. Harris K, Gooding P, Haddock G et al. Factors that contribute to psychological resilience to suicidal thoughts and behaviours in people with schizophrenia diagnoses: qualitative study. BJPsych Open 2019;5:e79. 300. Carver CS. You want to measure coping but your protocol’s too long: consider the Brief COPE. Int J Behav Med 1997;4:92-100. 301. Xie Y. Reliability and validity of the simplified Coping Style Questionnaire. Chinese J Clin Psychol 1998;6:114-5. 302. Magliano L, Fadden G, Madianos M et al. Burden on the families of patients with schizophrenia: results of the BIOMED I study. Soc Psychiatry Psychiatr Epidemiol 1998;33:405-12. 303. Friborg O, Hjemdal O, Rosenvinge JH et al. A new rating scale for adult resilience: what are the central protective resources behind healthy adjustment? Int J Methods Psychiatr Res 2003;12:65-76. 304. Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson resilience scale (CD-RISC). Depress Anxiety 2003;18:76-82. 305. Drayton M, Birchwood M, Trower P. Early attachment experience and recovery from psychosis. Br J Clin Psychol 1998;37:269-84. 306. Leamy M, Bird V, Le Boutillier C et al. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. Br J Psychiatry 2011;199:445-52. 307. Stuart SR, Tansey L, Quayle E. What we talk about when we talk about recovery: a systematic review and best-fit framework synthesis of qualitative literature. J Mental Health 2017;26:291-304. 308. Slade M, Blackie L, Longden E. Personal growth in psychosis. World Psychiatry 2019;18:29-30. 309. Whitley R, Shepherd G, Slade M. Recovery colleges as a mental health innovation. World Psychiatry 2019;18:141-2. 310. Corrigan PW. The impact of stigma on severe mental illness. Cogn Behav Pract 1998;5:201-22. 311. Brohan E, Elgie R, Sartorius N et al. Self-stigma, empowerment and perceived discrimination among people with schizophrenia in 14 European countries: the GAMIAN-Europe study. Schizophr Res 2010;122:232-8. 312. Ran MS, Zhang TM, Wong IY et al. Internalized stigma in people with severe mental illness in rural China. Int J Soc Psychiatry 2018;64:9-16. 313. Zhang TM, Wong IY, Yu YH et al. An integrative model of internalized stigma and recovery-related outcomes among people diagnosed with schizophrenia in rural China. Soc Psychiatry Psychiatr Epidemiol 2019;54:911-8. 314. Clement S, Schauman O, Graham T et al. What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychol Med 2015;45:11-27. 315. Ritsher JB, Otilingam PG, Grajales M. Internalized stigma of mental illness: psychometric properties of a new measure. Psychiatry Res 2003;121:31-49. 316. Boyd JE, Adler EP, Otilingam PG et al. Internalized Stigma of Mental Illness (ISMI) scale: a multinational review. Compr Psychiatry 2014;55:221-31. 317. Slade M. Recovery research: the empirical evidence from England. World Psychiatry 2012;11:162-3. 318. Sorsdahl KR, Kakuma R, Wilson Z et al. The internalized stigma experienced by members of a mental health advocacy group in South Africa. Int J Soc Psychiatry 2012;58:55-61. 319. Thornicroft G, Mehta N, Clement S et al. Evidence for effective interventions to reduce mental-health-related stigma and discrimination. Lancet 2016;387:1123-32. 320. Tsang HW, Ching SC, Tang KH et al. Therapeutic intervention for internalized stigma of severe mental illness: a systematic review and meta-analysis. Schizophr Res 2016;173:45-53. 321. Reed GM, Mendonça Correira J, Esparza P et al. The WPA-WHO Global Survey of Psychiatrists’ Attitudes Towards Mental Disorders Classification. World Psychiatry 2011;10:118-31. 322. Kishimoto T, Hagi K, Nitta M et al. Long-term effectiveness of oral second-generation antipsychotics in patient with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry 2019;18:208-24. 323. Dixon LB, Dickerson F, Bellack AS et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010;36:48-70. 324. Stovell D, Morrison AP, Panayiotou M et al. Shared treatment decision-making and empowerment-related outcomes in psychosis: systematic review and meta-analysis. Br J Psychiatry 2016;209:23-28.